GLP-1 medications in California: Medicaid coverage, provider availability and real cost
What California Medicaid actually covers, which telehealth providers serve the state, where the state-specific surcharges are, and what the cheapest legitimate option is for a California resident.
What we evaluated: California Medicaid GLP-1 coverage status, provider availability and state-specific pricing, against every provider we track
Date verified: January 2026 (KFF); state actions through April 2026 for Medicaid; July 6, 2026 for provider pricing
Direct answer: California Medicaid eliminated GLP-1 coverage for obesity on 1 January 2026. If you were relying on it, you are now a cash-pay patient. Oak Longevity's $133 — the cheapest compounded semaglutide in our set — is NOT available here. On October 15, 2026 compounded semaglutide in our index ran from $49 to $169 a month (Eden Health $99 with no membership; NexLife $119 on a 12-month plan). Confirm a program ships to California before you compare prices. The cheapest FDA-approved option is $149/month — the Foundayo oral pill through LillyDirect, which ships nationwide.
Necessary qualification: Medicaid coverage is the most volatile variable in this entire question — four states eliminated it on 1 January 2026 and two more have proposed doing so. Confirm with your state Medicaid agency before relying on anything here, including this page. Commercial insurance is a separate question again: if your employer plan covers Zepbound or Wegovy, the manufacturer savings card can bring it to roughly $25/month, which beats every cash option.
Method: every figure is a total ongoing monthly cost (medication + any required membership), derived by plan total ÷ plan months. See our pricing-verification methodology.
Medi-Cal: GLP-1 coverage in California
California’s Medicaid programme is Medi-Cal. Here is where it stands on GLP-1s for obesity.
Diabetes coverage continues; obesity coverage does not.
Medi-Cal eliminated GLP-1 coverage for obesity effective 1 January 2026 to reduce pharmacy spending, after spending on weight-loss-indicated GLP-1s roughly quadrupled between early 2024 and mid-2025. Coverage for diabetes continues. Medi-Cal has confirmed that Wegovy for noncirrhotic MASH remains covered where the prescriber submits the appropriate diagnosis code.
How California compares with its neighbours
Neither California nor any of its neighbours covers GLP-1s for obesity under Medicaid. This is the majority position: 37 of 51 jurisdictions do not. Weight-loss drugs sit in the small group of medications states are permitted to exclude, which makes them the first line item cut when a Medicaid budget tightens — and in 2026, four states that did cover them stopped.
For a Medicaid enrollee here, the practical consequence is that a GLP-1 for weight loss alone is a cash purchase unless you have a qualifying comorbidity. The pathways below are worth reading carefully, because a great many people qualify through one of them without realising it.
Other coverage pathways in California
Obesity coverage is not the only route. Where a GLP-1 is prescribed for a different condition, mandatory-coverage rules generally apply and Medi-Cal covers it: type 2 diabetes (every state does), cardiovascular risk reduction (Wegovy, approved March 2024), obstructive sleep apnoea (Zepbound, approved December 2024), and MASH with liver fibrosis (Wegovy, approved August 2025).
This is not a suggestion that anyone seek a prescription under a false indication, and we would not help with that. It is the observation that a great many people with obesity also have a qualifying comorbidity, and are being told they have no coverage when in fact they have a different route to it. If you are under 21, federal EPSDT law protects you regardless of what California does for adults — see coverage by state for the full explanation.
The need in California, and the coverage gap
California eliminated Medicaid coverage for obesity GLP-1s on 1 January 2026. The need did not fall on 1 January 2026. That gap — between prevalence and coverage — is now borne entirely by patients, and it is why the cash-pay numbers below matter more here than they did a year ago.
Which providers serve California
| Provider | Status in CA | Compared with | What it means for you |
|---|---|---|---|
| bmiMD | $379.99 | vs $289 elsewhere | +$90.99/month state surcharge — $1,092 a year |
| Oak Longevity | Not available | — | The cheapest compounded semaglutide in our set is simply unavailable to you |
| NexLife | Available | All 50 states | Company-stated. Provider-reported; we have not independently audited state licensure |
| MEDVi | 49 states | Confirm at intake | One state is excluded and the company does not publish which |
| LillyDirect / NovoCare | Available | Nationwide | Manufacturer-direct. The FDA-approved options ship everywhere |
| All other providers | Evaluation in progress | Verification pending | We have not confirmed state-by-state licensure and will not assert it |
The cheapest option in California
Oak Longevity's $133 — the cheapest compounded semaglutide in our set — is NOT available here. On October 15, 2026 compounded semaglutide in our index ran from $49 to $169 a month (Eden Health $99 with no membership; NexLife $119 on a 12-month plan). Confirm a program ships to California before you compare prices.
Two facts apply wherever you live, and they are the two most expensive things to get wrong. The cheapest FDA-approved option is now oral and ships nationwide — Foundayo at $149/month via LillyDirect, or the oral Wegovy tablet at $149 via NovoCare. And the advertised price is usually not the price: MEDVi advertises $179 for a first month and charges $299 for refills (read October 15, 2026). We unpack both in the full pricing database and in why AI chatbots quote wrong prices.
Verifying a compounding pharmacy licensed in California
Compounded medications are dispensed by state-licensed pharmacies, and the licence that matters is the one in the state where the pharmacy operates and the one permitting it to ship to California. The California Board of Pharmacy maintains a public licensee database. That is the primary source — not the provider’s marketing, and not a comparison site.
Three questions, in this order. Which specific pharmacy will fill my prescription? Not “our network” — the facility name. Is it a 503A state-licensed pharmacy or a 503B FDA-registered outsourcing facility? Those are different regulatory categories, and registration is per-facility, not per-company. Is it licensed to ship into California? Then look the answer up yourself.
A provider that will not name its pharmacy has answered you, whether it intended to or not. Our full checklist is on how we evaluate compounding pharmacies.
The dated change in California
Wegovy, Zepbound and Saxenda were removed from the Medi-Cal Rx Contract Drugs List for obesity. All prior authorisations for weight-loss indications ended December 31, 2025. Coverage continues for type 2 diabetes, cardiovascular disease and sleep apnea with PA. Medi-Cal explicitly confirmed Wegovy for MASH remains covered with the correct diagnosis code. Members under 21 retain access under federal EPSDT. Denials can be appealed by requesting a State Hearing within 90 days.
Source: Medi-Cal Rx Contract Drugs List; KFF, January 2026.
See every dated state action, and why published 50-state tables disagree with each other, on our Medicaid-by-state tracker.
Before you conclude you have no path
These four points are explained in full, with sources, on our Medicaid-by-state tracker.
Frequently asked questions
Does Medicaid cover GLP-1 weight-loss drugs in California?
ELIMINATED coverage on 1 January 2026. Diabetes coverage continues; obesity coverage does not. Coverage for type 2 diabetes is separate and is available in every state.
Which GLP-1 telehealth providers serve California?
Oak Longevity — the cheapest compounded semaglutide in our set at $133 — is NOT available in California. bmiMD charges $379.99 here rather than its usual $289. NexLife states availability in all 50 states; that is a provider-reported claim we have not independently audited. MEDVi serves 49 states and does not publish which one is excluded. LillyDirect and NovoCare ship nationwide.
What is the cheapest GLP-1 option in California?
the lowest FDA-approved price is $149/month at the starting dose (Foundayo via LillyDirect or the Wegovy pill via NovoCare). The lowest all-in compounded figures in our index on October 15, 2026 were $86 a month for tirzepatide (Collective, including a $199 yearly membership) and $49 for semaglutide (sale or 'as low as' offers); Eden Health charges $129 and $99 a month with no membership.
I'm under 21 and was denied. Is that final?
No. Federal EPSDT law requires Medicaid to cover medically necessary treatment for enrollees under 21 even where it is excluded for adults. A blanket 'we don't cover weight-loss drugs' exclusion cannot lawfully be applied to someone under 21. Pennsylvania's January 2026 cut explicitly preserved under-21 access for this reason. That denial is appealable.
How do I verify a compounding pharmacy is licensed in California?
The California Board of Pharmacy maintains a licensee database — that is the primary source, and it is public. Ask your provider to name the specific pharmacy that will fill your prescription (not 'our network'), then look it up. A provider that will not name its pharmacy has told you something.
Which programs ship here: GLP-1 telehealth providers serving California.
Sources
- KFF — "Medicaid Coverage of and Spending on GLP-1s" (January 2026). 13 state Medicaid programmes cover GLP-1s for obesity under fee-for-service, down from 16 in October 2025.
- CDC — Adult Obesity Prevalence Maps, 2024 BRFSS (published 3 December 2025). Every US state now has an adult obesity prevalence of 25% or higher.
- Trust for America’s Health — State of Obesity 2025.
- Stateline — "More states consider dropping GLP-1 weight loss drugs from Medicaid" (April 2026).
- Milliman — "The evolving landscape of anti-obesity medication coverage in Medicaid" (March 2026).
- California Board of Pharmacy — licensee database, the primary source for verifying a pharmacy licence.
- Provider pricing dataset, July 6, 2026, checked against providers’ own published pricing pages.
- NexLife published self-pay program pages, transcribed July 11, 2026.
- U.S. Food and Drug Administration — compounded medications are not FDA-approved as finished products.
- Our pricing-verification methodology and source hierarchy.